Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig A Hokanson

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Biomedicines|December 23, 2022
AXL-Receptor Targeted 14FN3 Based Single Domain Proteins (Pronectins™) from 3 Synthetic Human Libraries as Components for Exploring Novel Bispecific Constructs against Solid TumorsCraig A Hokanson, Emanuela Zacco, Guido Cappuccilli, et al.
Journal of Molecular Biology|January 20, 2009
Investigation of the biophysical and cell biological properties of ferroportin, a multipass integral membrane protein iron exporterAdrian E Rice, Michael J Mendez, Craig A Hokanson, et al.
Human Gene Therapy|March 28, 2003
Hybrid yeast-bacteria cloning system used to capture and modify adenoviral and nonviral genomesCraig A Hokanson, Emery Dora, Brian A Donahue, et al.
Protein Engineering, Design & Selection : PEDS|June 29, 2011
Engineering highly thermostable xylanase variants using an enhanced combinatorial library methodCraig A Hokanson, Guido Cappuccilli, Tatjana Odineca, et al.
Plant Biotechnology Journal|March 17, 2010
Production of therapeutic proteins in algae, analysis of expression of seven human proteins in the chloroplast of Chlamydomonas reinhardtiiBeth A Rasala, Machiko Muto, Philip A Lee, et al.
Cancers|March 29, 2023
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone SarcomasNicoletta Polerà, Antonia Mancuso, Caterina Riillo, et al.
Journal of Translational Medicine|May 4, 2023
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancerCaterina Riillo, Nicoletta Polerà, Maria Teresa Di Martino, et al.
Protein Science : a Publication of the Protein Society|May 25, 2026
Dual targeting of inhibitory EGFR epitopes with synthetic antibodies in therapeutic-resistant cancersJarrett J Adams, Evan Mallette, Max London, et al.
Protein Science : a Publication of the Protein Society|January 20, 2026
Tetravalent antibodies are more potent and efficacious erythropoiesis-stimulating agents than erythropoietin in vivoJarrett J Adams, Levi L Blazer, Jacky Chung, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Biomedicines|December 23, 2022
AXL-Receptor Targeted 14FN3 Based Single Domain Proteins (Pronectins™) from 3 Synthetic Human Libraries as Components for Exploring Novel Bispecific Constructs against Solid TumorsCraig A Hokanson, Emanuela Zacco, Guido Cappuccilli, et al.
Journal of Molecular Biology|January 20, 2009
Investigation of the biophysical and cell biological properties of ferroportin, a multipass integral membrane protein iron exporterAdrian E Rice, Michael J Mendez, Craig A Hokanson, et al.
Human Gene Therapy|March 28, 2003
Hybrid yeast-bacteria cloning system used to capture and modify adenoviral and nonviral genomesCraig A Hokanson, Emery Dora, Brian A Donahue, et al.
Protein Engineering, Design & Selection : PEDS|June 29, 2011
Engineering highly thermostable xylanase variants using an enhanced combinatorial library methodCraig A Hokanson, Guido Cappuccilli, Tatjana Odineca, et al.
Plant Biotechnology Journal|March 17, 2010
Production of therapeutic proteins in algae, analysis of expression of seven human proteins in the chloroplast of Chlamydomonas reinhardtiiBeth A Rasala, Machiko Muto, Philip A Lee, et al.
Cancers|March 29, 2023
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone SarcomasNicoletta Polerà, Antonia Mancuso, Caterina Riillo, et al.
Journal of Translational Medicine|May 4, 2023
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancerCaterina Riillo, Nicoletta Polerà, Maria Teresa Di Martino, et al.
Protein Science : a Publication of the Protein Society|May 25, 2026
Dual targeting of inhibitory EGFR epitopes with synthetic antibodies in therapeutic-resistant cancersJarrett J Adams, Evan Mallette, Max London, et al.
Protein Science : a Publication of the Protein Society|January 20, 2026
Tetravalent antibodies are more potent and efficacious erythropoiesis-stimulating agents than erythropoietin in vivoJarrett J Adams, Levi L Blazer, Jacky Chung, et al.
Pageof 1